- Summary
- Price Reports
- Price History
- Add To Your Stocklist
- View your Stocklist
- Basic Chart
- Interactive Chart
- Headlines
- Company Snapshot
- Summary Reports
- Free Annual Report
- Estimate Snapshot
- Estimate Report
- Mobile Quote
- Real-Time Quote
- Streaming Quote
|
Dyax | Company Snapshot
-
![]()
-
-
-
Vol:
-
Last Trade:
|
DYAX CORPORATION
Dyax Corp is a biopharmaceutical company that has developed and patented a method that is used to identify a broad range of compounds with potential for the treatment and diagnosis of diseases. The company is also using this method to identify compounds that could be used in purifying and manufacturing biopharmaceuticals and other chemicals. The company's phage display technology to rapidly and cost-effectively determine the potential medical uses of newly discovered proteins and genes and subsequently discover biopharmaceutical product candidates.
|
|
| Symbol: |
DYAX |
| Exchange(s): |
Nasdaq Stock Market |
| Industry: |
Consumer Products (Biotechnology & Pharmaceuticals) |
| 5-Star Rating: |
 |
|
ANNUAL FINANCIALS
|
|
|
Dec 31, 2008
12 Months
us$
|
Dec 31, 2007
12 Months
us$
|
Dec 31, 2006
12 Months
us$
|
3Yr.
Growth
% Change
|
|
Total Revenue ($000)
|
43,420
|
26,090
|
12,770
|
29.81
|
|
Earnings before Interest & Tax ($000)
|
-58,710
|
-47,220
|
-46,530
|
N/A
|
|
Profit/Loss ($000)
|
-66,460
|
-56,300
|
-50,320
|
N/A
|
|
Earnings per Share
|
-1.08
|
-1.06
|
-1.18
|
N/A
|
|
Total Assets ($000)
|
75,070
|
83,610
|
88,170
|
-0.37
|
|
Dividends Per Share
|
0.00
|
0.00
|
0.00
|
|
|
Return on Com. Equity
|
-1,406.56
|
-212.20
|
-156.30
|
|
|
Employees
|
N/A
|
N/A
|
N/A
|
|
|
|
|
|
Trailing 12 Month Results
|
|
|
12 Months ended
Dec 31, 2009,us$
|
12 Months ended
Dec 31, 2008,us$
|
%Change
|
|
Total Revenue ($000)
|
N/A
|
43,430
|
N/A
|
|
Profit/Loss ($000)
|
N/A
|
-66,460
|
N/A
|
|
Earnings per Share
|
N/A
|
-1.09
|
N/A
|
|
Dividends Per Share
|
0.00
|
0.00
|
|
Number of Shares
|
78,050,000
|
62,940,000
|
|
|
|
|
|
COMPANY INFORMATION
|
| Key Personnel |
| CEO: Henry E. Blair, Chmn. Presi.; C.E.O. |
| CFO: Stephen S. Galliker, Exec. V.P.; C.F.O.; Prin. Acct |
| |
| Contact Information |
| Address: |
300 Technology Square,
Cambridge,
MA,
02139 |
Phone: |
617-225-2500 |
| Fax: |
617-225-2501 |
| Web Address: |
www.dyax.com |
| E-Mail : |
ir@dyax.com |
| |
| Incorporation:
| United States |
| |
|
Securities:
|
DYAX-Q
|
|
| |
|
|
| |
|
|
Financial data is provided by Zacks Investment Research.
| |
All information on this site is compiled by CTVglobemedia Publishing Inc. from reliable industry sources. While all efforts are made to ensure the accuracy of the information, CTVglobemedia Publishing Inc. and its related entities assume no liability for incorrect, incomplete, or missing information from this site. Past performance is not necessarily indicative of future performance. Prior to making any investment decision, consult with a qualified investment advisor.
Copyright © 2010 CTVglobemedia Publishing Inc. All rights reserved.
|
|
|
